Neuphoria Therapeutics Inc/$NEUP
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Neuphoria Therapeutics Inc
Neuphoria Therapeutics Inc is a clinical-stage biotechnology company focused on therapies for serious central nervous system disorders. Its lead product candidate, BNC210, is an oral, proprietary, selective negative allosteric modulator of the alpha7 nicotinic acetylcholine receptor. The company has discontinued development of BNC210 for social anxiety disorder, while its BNC210 program for post-traumatic stress disorder is currently paused and no active clinical trial is underway. The company operates through a single operating and reporting segment focused on the discovery and development of allosteric ion-channel modulators for serious CNS disorders with high unmet medical need.
- Ticker
- $NEUP
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1
- Headquarters
- Millis, United States
- Website
- www.neuphoriatx.com
NEUP Metrics
BasicAdvanced
$15M
-
-$3.06
-
-
Price and volume
Market cap
$15M
52-week high
$5.53
52-week low
$2.62
Average daily volume
29K
Financial strength
Current ratio
27.847
Quick ratio
27.332
Total debt to equity
0.001
Profitability
EBITDA (TTM)
-8.347
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-1,145.66%
Operating margin (TTM)
-767.30%
Effective tax rate (TTM)
1.02%
Revenue per employee (TTM)
$1,170,000
Management effectiveness
Return on assets (TTM)
-19.65%
Return on equity (TTM)
-61.70%
Valuation
Price to revenue (TTM)
10.146
Price to book
0.6
Price to tangible book (TTM)
0.86
Price to free cash flow (TTM)
-0.964
Free cash flow yield (TTM)
-103.70%
Free cash flow per share (TTM)
-2.81
Growth
Revenue change (TTM)
-92.50%
Earnings per share change (TTM)
1,243.63%
10-year revenue growth (CAGR)
-21.55%
3-year earnings per share growth (CAGR)
494.60%
10-year earnings per share growth (CAGR)
61.66%
NEUP Financial Performance
Revenues and expenses
NEUP Earnings Performance
Company profitability
Upcoming events
No upcoming events
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.